Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Why Ozempic, Zepbound, and other weight-loss drug dupes carry risks
Poor purity can cause patients to experience fever, chills, nausea, skin irritation, infections and low blood pressure.
Most Americans who want to lose weight don’t want to take GLP-1 drugs like Wegovy and Zepbound, new survey says
Men, Baby Boomers, and postgraduate degree-holders were among those most likely to say they wouldn’t choose medication over dieting.
The end of a shortage of popular weight-loss drugs may mean many people lose access to them
Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a shortage of the brand-name drug has ended – which means compounding of the medicine must stop.
Mounjaro, Zepbound shortage eases as supplies of weight loss drug rebound
Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit cheaper copycat versions.
Offering Wegovy and other weight loss drugs on Medicare could cost $35 billion
Allowing Medicare to cover popular weight loss drugs such as Wegovy and Zepbound could increase federal spending by billions of dollars, according to a new report by the Congressional Budget Office (CBO).
What Is Wegovy? Doctors Explain the Injectable Weight-Loss Drug
While medications like Ozempic originally dominated the weight-loss space, Wegovy is another injectable prescription weight-loss drug worth knowing about. When properly prescribed, it's been shown to help people lose weight and keep it off,
Not Many Employers Cover GLP-1 Weight Loss Drugs
Fewer than 20% of large employers are covering GLP-1 weight loss drugs like Ozempic, a new KFF analysis shows.
37m
on MSN
Wegovy and Zepbound rival targeting 'next generation' of obesity drugs, Zealand Pharma CEO says
Danish biotech Zealand Pharma is targeting the "next generation" of weight loss drugs as competitors pile into a market ...
1d
A Major GLP-1 Drug Shortage Is Over. Some Patients Aren’t Celebrating
Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded ...
7d
Mounjaro and Zepbound Are No Longer in Shortage, F.D.A. Says
The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...
2d
Trade group sues FDA over ending Mounjaro/Zepbound shortage
A trade organization representing compounding pharmacies that make unbranded versions of the weight loss drugs Mounjaro and ...
20h
The Crackdown on Compounded GLP-1 Meds Has Begun
Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...
ConsumerAffairs
7d
Mountjaro, Zepbound removed from FDA's shortage list
The FDA has removed two of Eli Lilly's in-demand weight-loss and diabetes drugs from its shortage list. Diabetes drug ...
8d
Mounjaro and Zepbound no longer in shortage
After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...
17h
on MSN
Lilly Fires Warning Shot at Copycat Drug Makers After Shortage
Eli Lilly & Co. is ramping up its legal campaign against companies that were temporarily allowed to make and sell copycat ...
16h
Drugmakers are racing to find the next Wegovy. These obesity trials are ones to watch.
Data readouts over the next six months could set expectations for how the highly lucrative market for weight loss therapies ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Food and Drug Administration
Wegovy
Ozempic
Eli Lilly
Mounjaro
Feedback